| 0.087 0 (0%) | 04-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
Wed, 12 Apr 2023
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets - Yahoo Finance
Mon, 20 Sep 2021
A New Aspirin From PLX Has Investors’ Hearts Pounding - Barron's
Thu, 26 Aug 2021
PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today - Yahoo Finance
Mon, 14 Sep 2020
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - GlobeNewswire
Fri, 19 Jan 2018
Top Analyst Upgrades and Downgrades: Altria, Amex, Apple, Chipotle, IBM, Netflix, Nike, Sirius XM, Switch and More - 24/7 Wall St.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|